Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Analysts Review
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, May 14, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Brookdale Senior Living Inc. (NYSE: BKD), BioScrip Inc. (NASDAQ: BIOS), Emeritus Corp. (NYSE: ESC), Chemed Corp. (NYSE: CHE) and Kindred Healthcare Inc. (NYSE: KND). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2410-100free.
Brookdale Senior Living Inc. Analyst Notes
On May 7, 2014, Brookdale Senior Living Inc. (Brookdale) reported its Q1 2014 financial results with total revenue of $747.3 million, up 4.9% YoY. Net loss for the quarter came in at $2.3 million, compared to a net income of $3.6 million in Q1 2013. Loss per share stood at $0.02 in Q1 2014 compared to an earnings per share of $0.03 in Q1 2013. Cash From Facility Operations increased by 13.3% YoY to $79.2 million, or $0.64 per share during the quarter and is expected to range between $2.68 and $2.75 per share for full year 2014. The full analyst notes on Brookdale are available to download free of charge at:
BioScrip Inc. Analyst Notes
On May 8, 2014, BioScrip Inc. (BioScrip) reported its Q1 2014 financial results with revenue from continuing operations of $239.6 million, up 32.3% YoY. Net loss from continuing operations were $25.4 million, or $0.37 per basic and diluted share, compared to net loss from continuing operations of $8.4 million, or $0.15 per basic and diluted share in Q1 2013. Consolidated, adjusted EBITDA was $9.1 million, compared to $10.2 million in Q1 2013. Rick Smith, President and CEO of BioScrip commented, "Our first-quarter results reflect our success in achieving our two strategic priorities of building a leadership position in the home infusion industry and generating strong cash collections." He continued, "As one team, one company, we are already realizing greater efficiencies in our business and optimizing our productivity. At the same time, our cash collection efforts are yielding positive results and providing us with greater financial flexibility to execute our long-term plans." The full analyst notes on BioScrip are available to download free of charge at:
Emeritus Corp. Analyst Notes
On May 8, 2014, Emeritus Corp. (Emeritus) reported its Q1 2014 financial results with total operating revenue growth of 10.5% YoY to $521.8 million. According to Emeritus, the increase was driven primarily by the Company's acquisition of 38 communities in September 2013 pursuant to an operating lease with Health Care REIT, Inc. It also attributed the increase in revenues to improved occupancy and rate in the Consolidated Same Community portfolio as well as growth in the Company's ancillary services through the Nurse On Call, Inc. ("NOC") home health care subsidiary. Emeritus however reported net loss of $49.0 million compared to a loss of $39.7 million in Q1 2013. The full analyst notes on Emeritus are available to download free of charge at:
Chemed Corp. Analyst Notes
On April 29, 2014, Chemed Corp. (Chemed) reported its unaudited Q1 2014 financial results with revenue of $358 million, down 2.3% YoY. Net income was $20.6 million compared to $22.3 million in Q1 2013, and GAAP diluted EPS declined 4.3% YoY to $1.12. The Company anticipates full year 2014 earnings per diluted share (excluding non-cash expense for stock options, the non-cash interest expense related to the accounting for convertible debt, litigation and other discrete items) to be in the range of $5.90 to $6.10, as compared to $5.62 reported in 2013. The full analyst notes on Chemed are available to download free of charge at:
Kindred Healthcare Inc. Analyst Notes
On May 7, 2014, Kindred Healthcare Inc. (Kindred) announced that its Board of Directors has authorized and approved a regular quarterly cash dividend in the amount of $0.12 per common share. The dividend is payable on June 11, 2014 to shareholders of record as of the close of the business on May 21, 2014. The full analyst notes on Kindred are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.